


Aldeyra Is a Well-Capitalized Biotechnology Company with a Broad Immunology Pipeline



As of 6/30/2025, cash, cash equivalents, and marketable securities were \$81.9M, which Aldeyra believes will be sufficient to fund the Company into the second half of 2027.[‡]

[†]Regulatory review timelines are flexible and subject to change based on the regulator's workload and other potential review issues. [‡]Company guidance as of October 28, 2025; includes continued early and late-stage development of our product candidates in immune-mediated diseases. Guidance has not been updated or confirmed since October 28, 2025 and does not include any potential licensing or product revenue associated with reproxalap. NDA=New Drug Application

